PL398253A1 - Koniugat skladajacy sie z nosnika i zawiazanego z nim kowalencyjnie leku oraz ich zastosowanie - Google Patents

Koniugat skladajacy sie z nosnika i zawiazanego z nim kowalencyjnie leku oraz ich zastosowanie

Info

Publication number
PL398253A1
PL398253A1 PL398253A PL39825312A PL398253A1 PL 398253 A1 PL398253 A1 PL 398253A1 PL 398253 A PL398253 A PL 398253A PL 39825312 A PL39825312 A PL 39825312A PL 398253 A1 PL398253 A1 PL 398253A1
Authority
PL
Poland
Prior art keywords
conjugate
drug
carrier
covalently tied
tumor activity
Prior art date
Application number
PL398253A
Other languages
English (en)
Other versions
PL228735B1 (pl
Inventor
Tomasz Goszczynski
Janusz Boratyński
Joanna Wietrzyk
Beata Filip-Psurska
Katarzyna Kempińska
Original Assignee
Instytut Immunologii I Terapii Doswiadczalnej Pan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Immunologii I Terapii Doswiadczalnej Pan filed Critical Instytut Immunologii I Terapii Doswiadczalnej Pan
Priority to PL398253A priority Critical patent/PL228735B1/pl
Priority to PCT/EP2013/053974 priority patent/WO2013127885A1/en
Publication of PL398253A1 publication Critical patent/PL398253A1/pl
Publication of PL228735B1 publication Critical patent/PL228735B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest nanoczasteczka hybrydowa (koniugat) wykazujaca aktywnosc przeciwnowotworowa. Nanoczasteczka zbudowana jest z leku przeciwnowotworowego oraz hydroksyalkiloskrobi, korzystnie z metotreksatu (MTX) i hydroksyetylo skrobi (HES). Koniugat przejawia spotegowane dzialanie przeciwnowotworowe co wykazaly badania biologiczne in vitro oraz in vivo.
PL398253A 2012-02-27 2012-02-27 Zastosowanie koniugatu składającego się z nośnika i zawiązanego z nim kowalencyjnie leku PL228735B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL398253A PL228735B1 (pl) 2012-02-27 2012-02-27 Zastosowanie koniugatu składającego się z nośnika i zawiązanego z nim kowalencyjnie leku
PCT/EP2013/053974 WO2013127885A1 (en) 2012-02-27 2013-02-27 A conjugate of methotrexate and hydroxyethyl starch for use in the treatment cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL398253A PL228735B1 (pl) 2012-02-27 2012-02-27 Zastosowanie koniugatu składającego się z nośnika i zawiązanego z nim kowalencyjnie leku

Publications (2)

Publication Number Publication Date
PL398253A1 true PL398253A1 (pl) 2013-09-02
PL228735B1 PL228735B1 (pl) 2018-04-30

Family

ID=48193243

Family Applications (1)

Application Number Title Priority Date Filing Date
PL398253A PL228735B1 (pl) 2012-02-27 2012-02-27 Zastosowanie koniugatu składającego się z nośnika i zawiązanego z nim kowalencyjnie leku

Country Status (2)

Country Link
PL (1) PL228735B1 (pl)
WO (1) WO2013127885A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
CN112094320B (zh) * 2019-06-18 2022-08-02 首都医科大学 His-Gly-Glu修饰的甲氨蝶呤,其合成,抗肿瘤活性和应用
CN113041359B (zh) * 2021-03-26 2022-05-20 湖南师范大学 一种谷胱甘肽响应性抗骨肉瘤前药纳米粒子及其制备方法和用途
PL243572B1 (pl) * 2021-06-11 2023-09-11 Univ Medyczny Im Piastow Slaskich We Wroclawiu Glikokoniugatowa pochodna metotreksatu i glukozy oraz sposób jej otrzymywania i jej zastosowanie w leczeniu i zapobieganiu nowotworom

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528332A1 (en) 2003-06-09 2005-01-06 Aero International Products, Inc. Reversible inflation system
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation

Also Published As

Publication number Publication date
PL228735B1 (pl) 2018-04-30
WO2013127885A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
TR201909389T4 (tr) Terapötik nanopartikülleri hazırlamaya yönelik proses.
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
PH12015501814B1 (en) Novel insulin analog and use thereof
TWD161131S (zh) 保溫瓶
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
MX2016008448A (es) Conjugados de var2csa-farmaco.
EP2626427A3 (en) Sirna conjugate and preparation method thereof
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
CY1116100T1 (el) Παραγωγα πυριμιδινονης, η παρασκευη τους και η φαρμακευτικη τους χρηση
MX2015016469A (es) Fragmento fc de igg4 que comprende una region bisagra modificada.
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
MX342947B (es) Tratamiento de diabetes tipo 2.
IN2012DE01790A (pl)
PL398253A1 (pl) Koniugat skladajacy sie z nosnika i zawiazanego z nim kowalencyjnie leku oraz ich zastosowanie
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
TR201903918T4 (tr) Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
EA201100730A1 (ru) Комплекс включения пиноцембрина с циклодекстрином, способ его получения и применения
MX2015003343A (es) Tratamiento combinado con el farmaco de interferencia de netrina-1 y el farmaco quimioterapeutico.
PL401345A1 (pl) Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie
신재동 National health status in the light of the Korea welfare panel study
RU2012145705A (ru) Способ получения 3-пиридинил-1,5,3-дитиазепинанов
UA29447U (ru) Коллоидный раствор нанометаллов или смеси нанометаллов